GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » FCF Margin %

ObsEva (CHIX:OBSNZ) FCF Margin % : 40.34% (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is ObsEva FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ObsEva's Free Cash Flow for the three months ended in Dec. 2022 was CHF7.38 Mil. ObsEva's Revenue for the three months ended in Dec. 2022 was CHF18.29 Mil. Therefore, ObsEva's FCF Margin % for the quarter that ended in Dec. 2022 was 40.34%.

As of today, ObsEva's current FCF Yield % is 0.00%.

The historical rank and industry rank for ObsEva's FCF Margin % or its related term are showing as below:

CHIX:OBSNz' s FCF Margin % Range Over the Past 10 Years
Min: -121.19   Med: 0   Max: 0
Current: -121.19


CHIX:OBSNz's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -143.16 vs CHIX:OBSNz: -121.19


ObsEva FCF Margin % Historical Data

The historical data trend for ObsEva's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva FCF Margin % Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only - - - -227.20 -117.87

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.09 - - - 40.34

Competitive Comparison of ObsEva's FCF Margin %

For the Biotechnology subindustry, ObsEva's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's FCF Margin % distribution charts can be found below:

* The bar in red indicates where ObsEva's FCF Margin % falls into.



ObsEva FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

ObsEva's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-21.563/18.294
=-117.87 %

ObsEva's FCF Margin for the quarter that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=7.379/18.294
=40.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva FCF Margin % Related Terms

Thank you for viewing the detailed overview of ObsEva's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva Headlines

No Headlines